Phase 3Completed
Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
A Multi-Center Randomized Study of Vincristine, Doxil and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Multiple Myeloma
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (Industry)
- Enrolment
- 198 enrolled
- Conditions
- Multiple Myeloma; Myeloma; M-Protein; Myeloma Proteins
- Interventions
- Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
- Ages
- adults, older adults
- Registry
- NCT00344422
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine how well newly diagnosed multiple myeloma patients respond to an experimental regimen of Vincristine, DOXIL (doxorubicin HCl liposome injection) and Dexamethasone (VDD) versus the standard treatment of Vincristine, Doxorubicin and Dexamethasone (VAD).
Primary outcomes
- To determine and compare the objective response rate (the percentage of patients who attain an Objective Status of Complete Remission, Remission or Partial Remission) for patients receiving VDD vs VAD.
History
Last registry update
Registered
Study completion
Started